Dimethylamine enhances platelet hyperactivity in chronic kidney disease model

Area of Science:

• Nephrology
• Hematology
• Biochemistry

Background:

• Chronic kidney disease (CKD) is a global health concern linked to elevated dimethylamine (DMA) and altered platelet function.
• The precise relationship between DMA and platelet activation in CKD remains poorly understood.

Purpose of the Study:

• To elucidate the mechanism by which DMA influences platelet function in the context of CKD.
• To investigate the role of protein kinase C delta (PKCδ) in DMA-mediated platelet activation.

Main Methods:

• In vitro platelet assays and an in vivo murine model of CKD were employed.
• Assessed DMA levels, platelet activity, and renal function.
• Examined PKCδ and MEK1/2 signaling pathways via immunoblotting.
• Conducted rescue experiments using a PKCδ inhibitor and a choline-deficient diet.

Main Results:

• CKD mice exhibited elevated plasma DMA, heightened platelet activation, and impaired renal function.
• In vitro and in vivo studies confirmed DMA's ability to activate platelets.
• PKCδ inhibition counteracted DMA's pro-platelet effects.
• Dietary choline restriction reduced DMA levels and attenuated platelet activation in CKD mice.

Conclusions:

• Dimethylamine enhances platelet activation in a CKD model, potentially via PKCδ activation.
• Targeting DMA production or PKCδ signaling may offer therapeutic strategies for CKD-associated platelet dysfunction.